News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
453,493 Results
Type
Article (48605)
Company Profile (70)
Press Release (404818)
Section
Business (125461)
Career Advice (682)
Deals (18485)
Drug Delivery (61)
Drug Development (55712)
Employer Resources (66)
FDA (12912)
Job Trends (9563)
News (216977)
Policy (21193)
Tag
Academia (2770)
Alliances (31834)
Alzheimer's disease (944)
Approvals (12936)
Artificial intelligence (144)
Bankruptcy (149)
Best Places to Work (7737)
Breast cancer (165)
Cancer (1235)
Cardiovascular disease (97)
Career advice (618)
Cell therapy (212)
Clinical research (45502)
Collaboration (411)
Compensation (91)
COVID-19 (2054)
C-suite (139)
Data (1266)
Diabetes (149)
Diagnostics (4090)
Earnings (39362)
Events (57709)
Executive appointments (497)
FDA (13655)
Funding (384)
Gene therapy (137)
GLP-1 (430)
Government (3405)
Healthcare (13823)
Infectious disease (2122)
Inflammatory bowel disease (80)
IPO (7735)
Job creations (2139)
Job search strategy (571)
Layoffs (185)
Legal (4086)
Lung cancer (201)
Lymphoma (81)
Manufacturing (117)
Medical device (13107)
Medtech (13110)
Mergers & acquisitions (10985)
Metabolic disorders (374)
Neuroscience (1220)
NextGen: Class of 2025 (4634)
Non-profit (3381)
Northern California (1231)
Obesity (198)
Opinion (84)
Parkinson's disease (81)
Patents (95)
People (45959)
Phase I (13560)
Phase II (19838)
Phase III (15544)
Pipeline (438)
Postmarket research (2023)
Preclinical (5174)
Radiopharmaceuticals (174)
Rare diseases (177)
Real estate (3617)
Regulatory (14988)
Research institute (2072)
Southern California (1053)
Startups (2578)
United States (11574)
Vaccines (414)
Weight loss (141)
Date
Last 7 days (362)
Last 30 days (1519)
Last 365 days (21911)
2025 (2777)
2024 (22423)
2023 (25975)
2022 (34744)
2021 (37640)
2020 (36778)
2019 (32898)
2018 (25084)
2017 (22266)
2016 (21866)
2015 (25600)
2014 (19721)
2013 (17634)
2012 (18673)
2011 (18826)
2010 (17003)
Location
Africa (503)
Arizona (116)
Asia (30614)
Australia (5148)
California (2755)
Canada (1137)
China (339)
Colorado (152)
Connecticut (162)
Delaware (87)
Europe (60705)
Florida (461)
Georgia (119)
Illinois (348)
Indiana (197)
Japan (92)
Kansas (72)
Maryland (576)
Massachusetts (1920)
Michigan (111)
Minnesota (242)
New Jersey (934)
New York (835)
North Carolina (576)
Northern California (1231)
Ohio (130)
Pennsylvania (752)
South America (681)
Southern California (1053)
Texas (468)
Utah (99)
Washington State (250)
453,493 Results for "zhejiang chinese medical university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ADCs
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu
With an eye toward advancing a novel antibody-drug conjugate for gastrointestinal cancers, ArriVent is the latest biopharma player to ink a deal with a Chinese biotech.
January 22, 2025
·
2 min read
·
Tristan Manalac
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site
PharmaBlock Sciences, Inc., a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API GMP facility at its Zhejiang manufacturing site.
December 26, 2023
·
1 min read
IPO
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
January 22, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
January 14, 2025
·
3 min read
Policy
BIOSECURE Act Erodes Industry Confidence in Chinese Contractors: Report
Despite an uncertain legislative path to becoming law, the BIOSECURE Act has already impacted the biopharma industry’s confidence in Chinese service providers and prompted efforts to diversify manufacturing partners.
July 3, 2024
·
2 min read
·
Tristan Manalac
Press Releases
University Medical Centre Ljubljana and University Hospital of Maribor Elevate Antimicrobial Stewardship with DoseMeRx
January 15, 2025
·
3 min read
BioMidwest
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
Sermonix Pharmaceuticals Inc. today announced that China’s National Medical Products Administration (NMPA) approved the investigational new drug application (IND) for oral lasofoxifene (HLX78 in China) submitted with the assistance of Chinese development partner Shanghai Henlius Biotech, Inc. (2696.HK).
June 6, 2024
·
6 min read
Press Releases
Humanetics Publishes Groundbreaking Data on the Growth of the Chinese Population
November 25, 2024
·
4 min read
New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA
The Centre for Chinese Herbal Medicine Drug Development of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare disease, myofibrillar myopathy.
January 10, 2024
·
4 min read
Policy
Opinion: Chinese CDMOs and US Biopharma PR Strike a Precarious Balance
The PR departments of Chinese CDMOs affected by the BIOSECURE Act and their U.S. partners must step up to ensure proposed legislation doesn’t squash innovation.
May 21, 2024
·
5 min read
·
JX (Jaxon) Tan
1 of 45,350
Next
